Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.430
-0.110 (-4.33%)
At close: Aug 28, 2026, 4:00 PM EDT
2.430
-0.001 (-0.02%)
After-hours: Aug 28, 2026, 7:48 PM EDT
Fate Therapeutics Employees
Fate Therapeutics had 161 employees as of December 31, 2025. The number of employees decreased by 20 or -11.05% compared to the previous year.
Employees
161
Change (1Y)
-20
Growth (1Y)
-11.05%
Revenue / Employee
$40,317
Profits / Employee
-$782,584
Market Cap
291.16M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 161 | -20 | -11.05% |
| Dec 31, 2024 | 181 | 0 | - |
| Dec 31, 2023 | 181 | -370 | -67.15% |
| Dec 31, 2022 | 551 | 102 | 22.72% |
| Sep 30, 2022 | 545 | 155 | 39.74% |
| Jun 30, 2022 | 542 | 186 | 52.25% |
| Mar 31, 2022 | 511 | 197 | 62.74% |
| Dec 31, 2021 | 449 | 170 | 60.93% |
| Sep 30, 2021 | 390 | 111 | 39.78% |
| Jun 30, 2021 | 356 | - | - |
| Mar 31, 2021 | 314 | 136 | 76.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Invivyd | 122 |
| Lineage Cell Therapeutics | 77 |
| Cartesian Therapeutics | 75 |
| ALX Oncology Holdings | 48 |
| Vicore Pharma Holding AB | 46 |
| Anavex Life Sciences | 34 |
| Opus Genetics | 28 |
FATE News
- 13 days ago - Fate Therapeutics reports Q2 EPS (25c), consensus (26c) - TheFly
- 14 days ago - Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo - TheFly
- 14 days ago - Fate Therapeutics intiates first patient in RECLAIM-LN trial - TheFly
- 14 days ago - Fate Therapeutics price target raised to $8 from $6 at Piper Sandler - TheFly
- 16 days ago - Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis - GlobeNewsWire
- 17 days ago - Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - GlobeNewsWire
- 17 days ago - Fate Therapeutics Quarterly report: Q2 2026 - Filings
- 17 days ago - Fate Therapeutics Earnings release: Q2 2026 - Filings